Business Context and Reporting Period
Company: eXoZymes Inc. (Nasdaq: EXOZ)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: eXoZymes is a pre-revenue biotechnology company developing a synthetic biology platform for the scalable production of chemical molecules. The company completed its Initial Public Offering (IPO) in November 2024. It operates as a single reportable segment focused on research and commercialization of exozyme biosolutions.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,856,421) | $(1,008,458) |
| Net Loss Per Share (Basic & Diluted) | $(0.22) | $(0.16) |
| Total Operating Costs | $1,950,728 | $1,008,458 |
| Research & Development (Net of Grants) | $575,016 | $277,582 |
| General & Administrative | $1,375,712 | $730,876 |
| Cash and Cash Equivalents (End of Period) | $8,511,477 | $113,796 |
| Net Cash Used in Operating Activities | $(1,133,533) | $281,199 |
| Working Capital | $7,974,538 | N/A |
Note: Q1 2024 cash flow from operations was positive primarily due to cash received from related parties, which was not present in Q1 2025.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by 84.1% (from $1.01M to $1.86M) driven by a 93.4% increase in total operating costs.
- Expense Growth:
- General & Administrative (G&A): Increased 88.2% to $1.38M. Drivers include higher compensation (new staff not covered by grants), professional fees (audit/legal), IT infrastructure projects, and new D&O insurance costs.
- Research & Development (R&D): Net R&D expenses increased 107.2% to $575k. This reflects higher salaries, bonuses, and stock-based compensation, partially offset by a reduction in grant funding relative to expenses.
- Liquidity Position: Cash balances decreased by $1.21M during the quarter due to operational burn. However, the company maintains a strong cash position of $8.51M following the November 2024 IPO.
- Stock-Based Compensation: Increased to $317,277 in Q1 2025 from $142,810 in Q1 2024.
Outlook, Risks, and Management Commentary
- Going Concern: Management states there is "substantial doubt" about the company's ability to continue as a going concern due to anticipated funding shortfalls and pre-revenue status, despite current working capital sufficiency for the near term.
- Capital Resources: The company raised approximately $15.2M in net proceeds from its November 2024 IPO. Funds are being used for production expansion, staffing, R&D, and repayment of related party loans. No current arrangements for additional funding exist.
- Grant Funding: The company relies heavily on government grants (97% from Dept of Energy, 3% from NIH). Recent grants include a $1M DOD BioMADE cost-share grant and a $283k NIH BioClick grant. Management notes that grant funding levels can fluctuate.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting. While remediation is ongoing, disclosure controls were deemed not effective as of March 31, 2025.
- Risk Factors:
- Regulatory/Political: Potential impact of U.S. tariff changes, trade policy shifts, and reductions in federal research grants.
- Technology: Risk that the synthetic biology platform may not achieve commercial viability or regulatory approval.
- Market: Potential economic recession impacting capital markets and funding availability.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $1.13M quarterly operating cash burn against the $8.5M cash balance to estimate runway.
- Grant Dependency: Assess the stability of future government funding given the explicit risks regarding federal policy changes and grant reductions.
- Internal Controls: Monitor the progress of remediation for the disclosed material weaknesses in financial reporting.
- Revenue Timeline: Confirm the timeline for transitioning from pre-revenue R&D to commercial product sales, as no revenue was recognized in Q1 2025.
- Related Party Transactions: Review the status of the $135k payable to MDB Capital Holdings and any future related party financing needs.